From: False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients
 | Control (n = 60) | FNSN (n = 20) | P value |
---|---|---|---|
Age | 48 (35–73) | 48 (37–71) | 0.772 |
Operative method for breast cancer | 0.599 | ||
 Total mastectomy | 22 (37%) | 9 (45%) | |
 Partial mastectomy | 38 (63%) | 11 (55%) | |
Tumor size, cm, median (range) | 1.7 (0.3–3.2) | 1.8 (1.0–4.5) | 0.331 |
Tumor stage | > 0.999 | ||
 T1 | 43 (72%) | 14 (70%) | |
 T2 | 17 (28%) | 6 (30%) | |
Histological grade | 0.418 | ||
 Grade I | 18 (30%) | 3 (15%) | |
 Grade II | 20 (33%) | 8 (40%) | |
 Grade III | 22 (37%) | 9 (45%) | |
Extensive intraductal component | 21 (35%) | 5 (25%) | 0.582 |
Fascia invasion | 0 | 2 (10%) | 0.060 |
Skin invasion | 0 | 1 (5%) | 0.250 |
Nipple invasion | 0 | 2 (20%) | 0.103 |
Estrogen receptor | 0.750 | ||
 Negative | 12 (20%) | 3 (15%) | |
 Positive | 48 (80%) | 17 (85%) | |
Progesterone receptor | 0.433 | ||
 Negative | 25 (42%) | 6 (30%) | |
 Positive | 35 (58%) | 14 (70%) | |
HER2/Neu (Immunohistochemical staining) | > 0.999 | ||
 Negative | 52 (87%) | 18 (90%) | |
 Positive | 8 (13%) | 2 (10%) | |
Intrinsic subtypes | 0.761 | ||
 HmR-positive, HER2-negative | 43 (72%) | 16 (80%) | |
 HER2-enriched | 8 (13%) | 2 (10%) | |
 TNBC | 9 (15%) | 2 (10%) |